Critical care of the pediatric patient with rheumatic disease

Current Opinion in Pediatrics

Volumn 23, Issue 3, 2011, Pages 263-268

  Shulman, Andrew I ^a   Punaro, Marilynn ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

complications of pediatric rheumatic disease; critical care; intensive care unit; pediatric rheumatology

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; RITUXIMAB; STEROID;

ACUTE KIDNEY FAILURE; AIRWAY OBSTRUCTION; ANTIPHOSPHOLIPID SYNDROME; ARTERITIS; ARTICLE; AUTOIMMUNE CYTOPENIA; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD; CARDITIS; CAUSE OF DEATH; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CYTOPENIA; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG MEGADOSE; ENCEPHALITIS; GOODPASTURE SYNDROME; HEART FAILURE; HUMAN; HYPERTENSIVE CRISIS; HYPOPROTHROMBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTENSIVE CARE; INTERSTITIAL PNEUMONIA; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; LUNG EMBOLISM; LUNG FUNCTION TEST; LUNG HEMORRHAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE ACTIVATION SYNDROME; MECHANICAL RESPIRATORY FAILURE; MICROGNATHIA; PEDIATRIC INTENSIVE CARE NURSING; PERICARDITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATION CONTROL; RESPIRATORY FAILURE; RHEUMATIC DISEASE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; THROMBOCYTE; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULITIS; WEGENER GRANULOMATOSIS;

CHILD; CRITICAL CARE; HEMATOLOGIC DISEASES; HUMANS; INFECTION; INTENSIVE CARE UNITS, PEDIATRIC; MACROPHAGE ACTIVATION SYNDROME; RHEUMATIC DISEASES;

EID: 79958038494     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328346198f     Document Type: Article

References (50)

1. Radhakrishna SM, Shaham B, Marzan KAB, et al. Pediatric rheumatic disease in the intensive care unit: lessons learned from 15 years experience in a tertiary care pediatric hospital [abstract]. Arthritis Rheum 2010; 62:S879.
2. Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 2010; 22:561-566.
3. Miettunen PM, Narendran A, Jayanthan A, et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011; 50:417-419.
4. Kumar S, Benseler SM, Kirby-Allen M, Silverman ED. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics 2009; 123:e159-e163.
5. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61:29-36.
6. Hunt BJ. Pediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2008; 34:274-281.
7. Brunner HI, Freedman M, Silverman ED. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthritis Rheum 1999; 42:2346-2355. (Pubitemid 30333415)
8. Erkan D, Bateman H, Lockshin MD. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Lupus 1999; 8:560-564. (Pubitemid 29452571)
9. Taddio A, Brescia AC, Lepore L, Rose CD. Steady improvement of prothrombin levels after cyclophosphamide therapy in pediatric lupus anticoagulant hypoprothrombinemia syndrome (LAHPS). Clin Rheumatol 2007; 26:2167-2169. (Pubitemid 350120362)
10. Goldblatt F, Chambers S, Rahman A, Isenberg DA. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 2009; 18:682-689.
11. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.
12. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-220.
13. McCann LJ, Garay SM, Ryan MM, et al. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology (Oxford) 2007; 46:1363-1366. (Pubitemid 47244515)
14. Hassoun PM. Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med 2009; 30:429-439.
15. Prabu A, Patel K, Yee CS, et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford) 2009; 48:1506-1511.
16. Ringold S, Cron RQ. The temporomandibular joint in juvenile idiopathic arthritis: frequently used and frequently arthritic. Pediatr Rheumatol Online J 2009. doi: 10.1186/1546-0096-7-11.
17. Baker S, Parico L. Pathologic paediatric conditions associated with a compromised airway. Int J Paediatr Dent 2010; 20:102-111.
18. Tsuda E, Hirata T, Matsuo O, et al. The 30-year outcome for patients after myocardial infarction due to coronary artery lesions caused by Kawasaki disease. Pediatr Cardiol 2011; 32:176-182.
19. Kamen DL. How can we reduce the risk of serious infection for patients with systemic lupus erythematosus? Arthritis Res Ther 2009; 11:129.
20. Rahier JF, Moutschen M, Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49:1815-1827.
21. Yang LY, Chen WP, Lin CY. Lupus nephritis in children: a review of 167 patients. Pediatrics 1994; 94:335-340.
22. Klein A, Cimaz R, Quartier P, et al. Causes of death in pediatric systemic lupus erythematosus. Clin Exp Rheumatol 2009; 27:538-539.
23. Lee PP, Lee TL, Ho MH, et al. Recurrent major infections in juvenile-onset systemic lupus erythematosus: a close link with long-term disease damage. Rheumatology (Oxford) 2007; 46:1290-1296. (Pubitemid 47244503)
24. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009; 11:R109.
25. Shinjo SK, Bonfa E, Wojdyla D, et al. Antimalarial treatment may have a timedependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010; 62:855-862.
26. Nikpour M, Gladman DD, Ibanez D, Urowitz MB. Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus. Lupus 2009; 18:966-973.
27. Schmugge M, Revel-Vilk S, Hiraki L, et al. Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J Pediatr 2003; 143:666-669. (Pubitemid 37452799)
28. Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008; 50:822-825. (Pubitemid 351354792)
29. Harris EN, Pierangeli SS. Primary, secondary, and catastrophic antiphospholipid syndrome: what's in a name? Semin Thromb Hemost 2008; 34:219-226.
30. Avcin T, Cimaz R, Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an International Registry. Pediatrics 2008; 122:e1100-e1107.
31. Tarr T, Lakos G, Bhattoa HP, et al. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007; 16:39-45. (Pubitemid 46174314)
32. Falcini F, Taccetti G, Ermini M, et al. Catastrophic antiphospholipid antibody syndrome in pediatric systemic lupus erythematosus. J Rheumatol 1997; 24:389-392. (Pubitemid 27104108)
33. Canpolat N, Topal N, CivilibalM, et al. A case of catastrophic antiphospholipid syndrome in an adolescent girl with parvovirus B19 infection. Clin Pediatr (Phila) 2008; 47:593-597. (Pubitemid 351799239)
34. Iglesias-Jimenez E, Camacho-Lovillo M, Falcon-Neyra D, et al. Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics 2010; 125:e1523-e1528.
35. Nageswara Rao AA, Arteaga GM, Reed AM, et al. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer 2009; 52:536-538.
36. Vasoo S, Thumboo J, Fong KY. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. Lupus 2002; 11:443-450.
37. Arvidsson LZ, Smith HJ, Flato B, Larheim TA. Temporomandibular joint findings in adults with long-standing juvenile idiopathic arthritis: CT and MR imaging assessment. Radiology 2010; 256:191-200.
38. Arvidsson L, Fjeld M, Smith HJ, et al. Craniofacial growth disturbance is related to temporomandibular joint abnormality in patients with juvenile idiopathic arthritis, but normal facial profile was also found at the 27-year follow-up. Scand J Rheumatol 2010; 39:373-379.
39. Popat MT, Chippa JH, Russell R. Awake fibreoptic intubation following failed regional anaesthesia for caesarean section in a parturient with Still's disease. Eur J Anaesthesiol 2000; 17:211-214. (Pubitemid 30237299)
40. Punaro M, Abou-Jaoude P, Cimaz R, Ranchin B. Unusual neurologic manifestations (II): posterior reversible encephalopathy syndrome (PRES) in the context of juvenile systemic lupus erythematosus. Lupus 2007; 16:576-579. (Pubitemid 47359991)
41. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34:1133-1138. (Pubitemid 46774861)
42. Parodi A, Davi S, Pringe AB, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 2009; 60:3388-3399.
43. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56:965-971. (Pubitemid 46399444)
44. HazenMM, Woodward AL, Hofmann I, et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum 2008; 58:567-570. (Pubitemid 351294892)
45. Villanueva J, Lee S, Giannini EH, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7:R30-R37.
46. Zhang K, Biroschak J, Glass DN, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 2008; 58:2892-2896.
47. Allantaz F, Chaussabel D, Stichweh D, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007; 204:2131-2144. (Pubitemid 47360874)
48. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201:1479-1486. (Pubitemid 40664091)
49. Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to antiinterleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58:1505-1515. (Pubitemid 351705940)
50. Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465:937-941.